Prognostic and predictive factors in resected non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Opinion in Medical Diagnostics

• Publication date

  2010-08-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/17530059.2010.506214PMID 23496196
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.

  2010cited by this paper
• Overexpression of the Mammalian Target of Rapamycin: A Novel Biomarker for Poor Survival in Resected Early Stage Non-small Cell Lung Cancer

  2010cited by this paper
• MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

  2010cited by this paper
• High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma

  2009cited by this paper
• BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer

  2009cited by this paper
• Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

  2009cited by this paper
• Correlation of angiogenesis with 18F‐FMT and 18F‐FDG uptake in non‐small cell lung cancer

  2009cited by this paper
• Prognostic significance of L‐type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung

  2009cited by this paper
• CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases

  2009cited by this paper
• L‐type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non‐small cell lung cancer

  2009cited by this paper
• Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer

  2009cited by this paper
• 18F-FMT Uptake Seen Within Primary Cancer on PET Helps Predict Outcome of Non–Small Cell Lung Cancer

  2009cited by this paper
• Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

  2009cited by this paper
• System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma.

  2009cited by this paper
• Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer

  2008cited by this paper
• DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

  2007cited by this paper
• The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.

  2007cited by this paper
• Biological correlates of FDG uptake in non-small cell lung cancer.

  2007cited by this paper
• Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.

  2007cited by this paper
• The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer

  2007cited by this paper
• Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data.

  2007cited by this paper
• Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients.

  2007cited by this paper
• Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.

  2007cited by this paper
• BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer

  2007cited by this paper
• Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study

  2007cited by this paper
• Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials

  2006cited by this paper
• Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.

  2006cited by this paper
• RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

  2006cited by this paper
• Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer

  2005cited by this paper
• ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.

  2005cited by this paper
• [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.

  2005cited by this paper
• Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

  2005cited by this paper
• Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.

  2005cited by this paper
• Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances.

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.

  2004cited by this paper
• Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

  2004cited by this paper
• Excision repair cross complementing-group 1: gene expression and platinum resistance.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage.

  2004cited by this paper
• Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging.

  2004cited by this paper
• Phospho-Akt Overexpression in Non–Small Cell Lung Cancer Confers Significant Stage-Independent Survival Disadvantage

  2004cited by this paper
• Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1alpha in non-small cell lung cancers.

  2004cited by this paper
• Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC.

  2004cited by this paper
• Le traitement chirurgical du cancer bronchique non à petites cellules

  2004cited by this paper
• Dysregulation of the TSC-mTOR pathway in human disease

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC).

  2003cited by this paper
• Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis

  2003cited by this paper
• Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

  2003cited by this paper
• Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.

  2003cited by this paper
• Non‐small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study

  2002cited by this paper
• VEGF and the quest for tumour angiogenesis factors

  2002cited by this paper
• The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

  2002cited by this paper
• BRCA1: mechanisms of inactivation and implications for management of patients.

  2002cited by this paper
• Prognostic factors in non-small cell lung cancer: a decade of progress.

  2002cited by this paper
• Sequential assembly of the nucleotide excision repair factors in vivo.

  2001cited by this paper
• Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer.

  2001cited by this paper
• Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.

  2000cited by this paper
• Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer

  2000cited by this paper
• The Ki‐67 protein: From the known and the unknown

  2000cited by this paper
• Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing.

  2000cited by this paper
• Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer.

  2000cited by this paper
• Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

  2000cited by this paper
• L-leucine availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-regulation of system A amino acid transport.

  2000cited by this paper
• K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

  1999cited by this paper
• Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.

  1999cited by this paper
• p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.

  1999cited by this paper
• p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells

  1999cited by this paper
• Ribonucleotide reductases in the twenty-first century.

  1998cited by this paper
• Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

  1997cited by this paper
• Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study.

  1997cited by this paper
• Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival

  1997cited by this paper
• The proto-oncogene Bcl-2 and its role in regulating apoptosis

  1997cited by this paper
• The proto-oncogene Bcl-2 and its role in regulating apoptosis

  1997cited by this paper
• Immunocytochemical markers in stage I lung cancer: relevance to prognosis.

  1997cited by this paper
• Synthesis of isomers of 18F‐labelled amino acid radiopharmaceutical: Position 2− and 3‐L‐18F-α‐methyltyrosine using a separation and purification system

  1997cited by this paper
• Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents

  1996cited by this paper
• Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling.

  1992cited by this paper
• The use of fdg pet in differentiating infectious from malignant central nervous system lesions in patients with aids

  1992cited by this paper
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

  1990cited by this paper
• Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.

  1987cited by this paper
• Progression

  1896cited by this paper

• BCL2, IRS1, AKT3, PTEN, and HIF1A expression levels in non‐small cell lung cancer patients

  2025cites this paper
• A prognostic PET radiomic model for risk stratification in non-small cell lung cancer: integrating radiogenomics and clinical features to predict survival and uncover tumor biology insights

  2025influential citation
• Clinical significances of p27 in digestive tract cancers: a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data

  2018cites this paper
• Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization

  2017cites this paper
• Prognostic Role of ERCC 1 Protein Expression and its Correlation with 18 F-FDG Uptake on PET in Patients with Resected Non-Small Cell Lung Cancer

  2017cites this paper
• Significance of circulating tumor cells in non-small-cell lung carcinoma

  2017cites this paper
• Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.

  2015cites this paper
• Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I–III Non-Small Cell Lung Cancer

  2015cites this paper
• The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy

  2013cites this paper
• ¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?

  2012cites this paper
• Depolarized MUC1 Expression Is Closely Associated With Hypoxic Markers and Poor Outcome in Resected Non–Small Cell Lung Cancer

  2012cites this paper
• Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer.

  2011cites this paper
• Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.

  2011cites this paper
• Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and &bgr; III-Tubulin in Thymic Epithelial Tumors

  2011cites this paper